XML 31 R43.htm IDEA: XBRL DOCUMENT v2.4.0.6
ALLIANCES AND COLLABORATIONS (Pfizer) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Dec. 31, 2011
Alliances and Collaborations Statement [Line Items]          
Net sales $ 4,443 $ 5,434 $ 9,694 $ 10,445  
ELIQUIS [Member]
         
Alliances and Collaborations Statement [Line Items]          
Net sales 1   1    
Pfizer [Member] | ELIQUIS [Member]
         
Alliances and Collaborations Statement [Line Items]          
Net sales 1   1    
Percentage reimbursement of development costs from collaboration partner 60.00%   60.00%    
Commercialization expense reimbursements to/(from) Pfizer (3) (2) (8) (3)  
Research and development reimbursements to/(from) collaboration partner 9 (27) 11 (56)  
Amortization income - upfront, milestone and other licensing payments (9) (8) (19) (16)  
Deferred income 415   415   434
Pfizer [Member] | ELIQUIS [Member] | Upfront, milestone and other licensing payments [Member]
         
Alliances and Collaborations Statement [Line Items]          
Total upfront, milestone and other licensing payments $ 559   $ 559